Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 30, Issue 5, 2011, Pages 697-701

  Bao, Jun ^a   Yue, Tao ^b   Liu, Wei ^a   Zhang, Qing ^a   Zhou, Ling ^a   Xu, Hu Ji ^a   Dai, Sheng Ming ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Guanghua Rheumatology Hospital   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Arthritis; Combination; Drug therapy; Drug tolerance; Interleukin 1 receptor antagonist protein; Rheumatoid

Indexed keywords

METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHINA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 79959712981     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-010-1654-5     Document Type: Article

References (12)

1. Bresnihan B, Cobby M (2003) Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology 42: ii22-ii28
2. Burger D, Dayer JM (2006) Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20:879-896
3. Genovese MC, Cohen S, Moreland L et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412-1419 (Pubitemid 38608062)
4. Buch MH, Bingham SJ, Seto Y et al (2004) Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum 50:725-728 (Pubitemid 38326170)
5. Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735
6. Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis Rheum 48:35-45 (Pubitemid 36091645)
7. Potter C, Hyrich KL, Tracey A et al (2009) Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumor necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68:69-74
8. Johnsen AK, Plenge RM, Butty Vet al (2008) A broad analysis of IL1 polymorphism and rheumatoid arthritis. Arthritis Rheum 58:1947-1957 (Pubitemid 351988086)
9. Anderson AE, Isaacs JD (2008) Tregs and rheumatoid arthritis. Acta Reumatol Port 33:17-33
10. Lawson CA, Brown AK, Bejarano V et al (2006) Early rheumatoid arthritis is associated with a deficit in the CD4 +CD25+high regulatory T cell population in peripheral blood. Rheumatology 45:1210-1217 (Pubitemid 44548851)
11. van Amelsfort JM, van Room JA, Noordegtaaf M et al (2007) Proinflammatory mediator-induced reversal of CD4+CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum 56:732-742
12. Brinster C, Shevach EM (2008) Costimulatory effects of IL-1 on the expansion/differentiation of CD4+CD25+Foxp3+ and CD4 +CD25+Foxp3- T cells. J Leukoc Biol 84:480-487